Cargando…
A rationale for surgical debulking to improve anti-PD1 therapy outcome in non small cell lung cancer
Anti-PD1 immunotherapy has emerged as a gold-standard treatment for first- or second-line treatment of stage IV NSCLC, with response rates ranging from 10 to 60%. Strategies to improve the disease control rate are needed. Several reports suggested that debulking surgery enhances anti-tumor immunity....
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6858444/ https://www.ncbi.nlm.nih.gov/pubmed/31729430 http://dx.doi.org/10.1038/s41598-019-52913-z |